CCR7 and myeloid sarcoma: We observed similar percentages of naïve, TSCM (CCR7+CD45RA+ CD28+CD27+CD95+), CM (CCR7+CD45RA−), TM (CCR7−CD45RA−CD28+), and EM (CCR7−CD45RA−) cells as far as age-matched donors, and MS patients (HD_RR vs. RR and HD_PR vs. PR) were compared.